Free Newsletter
Drug marketing costs double R&D
Every self-respecting pharma exec will tell you: R&D is the industry's peculiar burden, the chief reason why brand-name drugs are so expensive. But the average Joe or Jane consumer thinks that's, er, a lot of bunk. It's marketing that drives the costs of their meds ever upward.
Now, a couple of academics have the figures. After combing through market research, they found that pharma spent $57.5 billion on marketing in 2004--almost twice the $31.5 billion spent on research that year, according to the National Science Foundation. And the research numbers include public funding, not just company expenses.
The data "confirms the public image of a marketing-driven industry," the study authors wrote. It also shows that the industry needs to be redirected toward research and away from brand-building, they wrote. Just how might that redirection happen? They didn't say.
- see this release release
-get the journal article from PLoS Medicine
Related Articles:
Study: DTC ad spending on the rise. Report
10 reforms for drug advertising. Report
FDA to study TV drug ad imagery. Report
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline


SHARE
WITH: